Please use this identifier to cite or link to this item:
Title: Protective effect of aqueous extract of <i>Bombax malabaricum</i> DC on experimental models of inflammatory bowel disease in rats and mice
Authors: Jagtap, A G
Niphadkar, P V
Phadke, A S
Keywords: <i>Bombax malabaricum</i>
Inflammatory bowel disease
Issue Date: May-2011
Publisher: NISCAIR-CSIR, India
Abstract: There is little evidence regarding role of <i>B. malabaricum</i> in the treatment of inflammatory bowel disease (IBD); though it is clinically employed as a constituent of a polyherbal preparation for IBD. To establish its role as a monotherapy for IBD, preliminary phytochemical screening of aqueous extract of <i>B. malabaricum</i> (AEBM) was undertaken. Subsequently, its protective effect in indomethacin and iodoacetamide induced colitis in rats (45, 90, 180, 270 mg/kg) and acetic acid induced colitis in mice (65, 130, 250, 500 mg/kg) was assessed. AEBM (270 mg/kg) in indomethacin and iodoacetamide induced colitis significantly reduced the ulcer score and myeloperoxidase (MPO) activity. AEBM/500 mg/kg dose/significantly reduced the ulcer score and MPO activity in acetic acid induced colitis. The extract (270 mg/kg in rats and 500 mg/kg in mice) was found to be comparable with prednisolone (10 mg/kg) and 5-aminosalicylic acid (5-ASA) (100 mg/kg) used as standard treatments. AEBM provided reduction in edema of the intestinal tissues, ulcer protection and lowering of MPO activity in a dose dependent manner. AEBM (500 mg/kg) significantly reduced colonic and serum TNF-α level when compared with the positive control in acetic acid induced colitis model. The results suggest a protective role of AEBM in IBD.
Description: 343-351
ISSN: 0975-1009 (Online); 0019-5189 (Print)
Appears in Collections:IJEB Vol.49(05) [May 2011]

Files in This Item:
File Description SizeFormat 
IJEB 49(5) 343-351.pdf958.05 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.